One Page. The Whole Case.
A Clear Next Step.
A de-identified example of a Dr PreZiGen interpretation for metastatic periampullary adenocarcinoma with germline BRCA2 — showing how clinical history, genomics and evidence come together in the Dr PreZiGen Drug Score.
Click the report to enlarge
Reading the Drug Score
The score reflects strength and specificity of evidence for this patient — not just whether a drug is approved.
Strong
Guideline-supported or variant-specific clinical evidence in a matching setting, with no major contraindication for this patient.
Moderate
Reasonable evidence with caveats — prior exposure, partial match of setting, or patient-specific factors that temper expected benefit.
Low
Cross-resistance, no supporting biomarker, unconfirmed alteration or pre-clinical data only.
Every Tumour Has a Story. Let Us Read Yours.
Send the reports you have — pathology, genomics, imaging summaries and treatment history. We'll return a report like this, plus a call to talk it through.